



BUSINESS PLAN · INDIA

Online Pharmacy / E-pharmacy

A medicine order history is a diagnosis - so the data is not an asset

PHARMACY RETAIL & DISTRIBUTION

AISEVAK.IN · BY ABL DIGITAL TECHNOLOGIES

August 2026

This document is confidential and prepared for planning purposes. All financial figures are illustrative model assumptions for an Indian MSME context and must be validated against live quotes, local rates and professional advice before any investment or borrowing decision.

1. Executive Summary

This plan sets out an **Online Pharmacy / E-pharmacy** in India — a licensed digital medicine business built on chronic-care subscription refills, acute prescription orders, OTC, nutraceuticals and home diagnostics, with fulfilment centres in four cities and a last-mile network, handling roughly 1.62 million orders a year by Year 3.

This plan inherits the pharmacy anchor's rules and applies them to a pharmacy with no counter, no eye contact — and a perfect memory. **The anchor established that the refusal rate is the only honest metric where the harm of a sale lands on somebody other than the buyer. Here that is true and one thing more is true: the shop remembers everything, forever, about millions of people.**

☐ **A MEDICINE ORDER HISTORY IS A DIAGNOSIS.** What somebody buys from a pharmacy discloses HIV status, pregnancy and its termination, mental illness, cancer, fertility treatment, addiction and a great deal else — **WITH NO CLINICAL RECORD REQUIRED, NO DOCTOR INVOLVED AND NO INFERENCE MORE COMPLICATED THAN READING THE MOLECULE NAME.** An e-pharmacy holds that dataset on millions of people; it is by a wide margin the most commercially valuable asset the business owns; and it is buyable — by insurers pricing risk, by lenders scoring applicants, by employers, by pharmaceutical marketers wanting to reach the diagnosed. The customer consented in a checkbox he did not read at eleven at night while ill. So this business **NEVER SELLS, SHARES, SEGMENTS OR TARGETS ON MEDICINE DATA, RUNS NO THIRD-PARTY ANALYTICS OR ADVERTISING SDK ANYWHERE ON THE ORDER FLOW, PUBLISHES WHAT IT REFUSED TO SELL AND WHAT IT WAS WORTH** — eleven approaches in Year 3 valued at ₹9.20 crore, **ROUGHLY TWICE THE ENTIRE YEAR'S PROFIT** — and makes deletion real within seven days. **WHERE THE RECORD OF A PURCHASE IS ITSELF THE PRIVATE FACT, THE DATA IS NOT AN ASSET — HOLDING IT IS A LIABILITY YOU ACCEPTED ON THE CUSTOMER'S BEHALF.**

☐ **AND THE PRESCRIPTION UPLOAD IS VERIFIED BY NOBODY.** It is an image: reusable across orders and accounts, expirable, editable, and frequently somebody else's. Refusing is even cheaper to skip here than at a counter, because no one is standing in front of you, the conversation is asynchronous, and the thing the whole organisation is optimised to improve is conversion. So every order is **REVIEWED BY A REGISTERED PHARMACIST, 29,400 ORDERS WERE REFUSED** in Year 3 at 18.1 per thousand and ₹2.68 crore forgone, reuse and expiry are detected across accounts, and — per the anchor — **A REVIEWER WITH A ZERO REFUSAL RATE IS AUDITED RATHER THAN PRAISED.**

☐ **AND THE REFILL REMINDER IS A SALES TRIGGER DRESSED AS CARE.** The clinical reminder is separated from the promotion, and **NIL discretionary-category nudges are fired off a prescription signal** — no supplement is ever recommended alongside a diagnosis.

This plan models an operator requiring **₹18.00 crore** (₹8.20 crore investor + ₹5.40 crore term loan + ₹2.60 crore promoter + ₹1.80 crore working capital), moving from **₹24.00 crore revenue and a ₹3.97 crore loss** to **₹146.00 crore revenue and ₹4.96 crore profit** by Year 3 — a 3.4% net margin and 23.0% return on capital. (E-pharmacy — figures illustrative.)

2. Business Description, Vision & Legal Structure

Concept: A pharmacy that refuses to know you commercially.

Vision: To be the medicine business whose most valuable asset it has permanently declined to use.

Mission: Review every prescription with a real pharmacist and publish what we refused; never sell, share or segment on what a person's medicines reveal; keep advertising technology off the order flow entirely; separate the clinical reminder from the promotion; and delete when asked, properly, within a week.

Legal structure

- **Private Limited** — recommended. Drug licences per fulfilment site, platform contracts, institutional capital and data obligations all assume it.
- **LLP** — unsuited: this business raises equity in rounds and carries regulated licences.
- **Data governance function reporting to the board, with a veto over any data proposal — because the asset it is protecting is worth twice the company's annual profit.**

Regulatory anchor: the Drugs and Cosmetics Act 1940 and Rules 1945, with a **retail drug licence for each fulfilment premises** from which dispensing occurs; the Pharmacy Act 1948, under which **dispensing must be by or under the personal supervision of a registered pharmacist — a requirement that does not soften because the patient is at the other end of an application**; Schedules H, H1 and X, with the H1 register maintained per dispensing site; the **Digital Personal Data Protection Act 2023**, under which **health data is sensitive personal data requiring purpose limitation, informed consent, breach notification and honoured erasure**; NPPA and DPCO ceiling prices; the Information Technology Act and the CERT-In directions; cold-chain conditions for thermolabile products; FSSAI for nutraceuticals sold through the same basket under a different law; consumer protection and e-commerce rules on dark patterns and pre-ticked consents; GST, and EPF/ESI and POSH. **The decisive structural fact is that the online channel's regulatory framework has been contested and repeatedly revisited, so a responsible operator must run to the STRICTER reading of an unsettled position rather than the more convenient one — and that nothing in any of it obliges a platform to disclose what it does with the inference that a customer takes insulin.**

3. Promoter & Ownership

Led by a promoter with pharmacy, healthcare or consumer-technology background. Three competences decide outcomes. *Unit economics after delivery*, because e-pharmacy has destroyed more capital than almost any Indian consumer category by growing orders that lose money. *Regulated fulfilment*, since a licensed dispensing site with cold chain is not a warehouse with a pharmacist attached. And *the discipline to leave the data alone*, which is where this plan's proposition sits and which becomes harder, not easier, as the dataset grows and the offers improve. Ownership, equity & investor terms are editable inputs; **the data governance function reports to the board, holds a veto over any proposal touching order data, and every approach received is logged whether or not it was entertained.**

4. Market Analysis — India

A large, discount-led, chronically unprofitable category with one asset nobody discusses in public.

Demand drivers

- **Chronic disease and repeat monthly demand** — the only durable economics in the category.
- **Price transparency** across a fragmented, opaque retail trade.
- **Home delivery** for the elderly, the immobile and the working.
- **Smartphone and digital-payment penetration** beyond the metros.
- **Privacy of purchase** for categories a customer will not ask for across a counter.
- **Teleconsultation adjacency** creating a legitimate prescription flow.

Market sizing (illustrative framing)

Layer	Definition	Indicative scale
TAM	Indian retail medicine spend	Very large; online share still small
SAM	Orders that are contribution-positive AFTER delivery , not gross orders	Bounded by CHRONIC SUBSCRIBERS, not by app installs
SOM (Yr 1-3)	Orders across four fulfilment cities	₹24cr → ₹146cr; ~1.62 million orders; 78% chronic retention

Revenue mix and share (Year 3)

Stream	Share of revenue	Gross margin — and what it does to behaviour
Chronic-care subscription refills	40.0%	18.0% — the whole business, and the lowest margin
Acute prescription orders	25.0%	20.0% — where the upload is least likely to be genuine
OTC medicines	12.0%	30.0% — recommended by an algorithm, not a person
Nutraceuticals, supplements & wellness	9.0%	46.0% — the ladder's top rung, automated
Surgicals, devices & home diagnostics	8.0%	32.0% — genuine need, discretionary timing
Fulfilment & last-mile for partner pharmacies	6.0%	24.0% — capacity sold, no prescription risk

The anchor's margin ladder reappears here in its automated form, and automation makes it worse in a specific way: at a counter the supplement is suggested by a person who can see the patient and might not bother, whereas online the recommendation is a rule that fires on every qualifying order, at scale, at no marginal cost, forever. A supplement engine that lifts attach rate by three points across 1.62 million orders is worth more than any pharmacist's counter suggestion could ever be, and it never has a bad day or an attack of conscience. So the rule here is stricter than the anchor's disclosure rule: **NO ALGORITHMIC RECOMMENDATION OF A DISCRETIONARY CATEGORY IS FIRED OFF A PRESCRIPTION SIGNAL AT ALL**. Not disclosed — not done. A customer buying metformin is never shown a diabetes supplement, because the recommendation would be built on a diagnosis he disclosed in order to be dispensed, not in order to be marketed to.

Constraints

- **Contribution after delivery**, which is the number the category has historically ignored.
- **Regulatory unsettledness** in the online channel, requiring the stricter reading.
- **Cold chain in last-mile**, where an excursion is invisible on arrival.
- **Discounting**, which is the category's default competitive move and destroys the thin margin.

5. Competition & Position

Competitor type	Strength	Weakness this plan exploits
Large funded e-pharmacies	Scale, buying power, brand, delivery density, capital	Order data monetised; ad SDKs on the flow; upload review nominal
Quick-commerce platforms adding medicines	Ten-minute delivery, existing customers, dense dark stores	Speed target incompatible with a real prescription review

Retail chains with delivery apps	Physical shops, pharmacists, licences already held	App is an order channel; data practice inherited from marketing
Neighbourhood chemists on messaging apps	Trust, credit, personal knowledge, no acquisition cost	No record discipline; no cold-chain evidence
This plan	No data monetisation, no ad SDK on the order flow, published refusal rate, real pharmacist review	3.4% net; declines ₹9.20cr of data revenue a year

The positioning is a promise about restraint, which is the hardest kind to make credible — so every element of it is built to be checkable rather than asserted. A customer, a journalist or an auditor can inspect the application's network traffic and find **NO** third-party analytics or advertising SDK anywhere on the order flow; can request deletion and see it completed within seven days; can read the published log of data approaches received and declined, with values; and can read the refusal rate. This library's standing test is whether an ordinary customer can verify a claim within one interaction, and a privacy claim that cannot be inspected is indistinguishable from a privacy claim that is false — which is precisely why the category's existing assurances persuade nobody.

The cost of the honest position is stated in rupees, and here it comes in two very different sizes. The operating commitments total ₹4.94 crore against ₹4.96 crore of Year-3 profit: pharmacist review and refusals ₹2.68 crore, separating the clinical reminder from the promotion and firing no discretionary nudges off a prescription signal ₹1.16 crore, running no third-party analytics or advertising SDK on the order flow ₹68 lakh, and destroying failed cold-chain deliveries rather than restocking them ₹42 lakh. And then, separately and much larger: **THE DATA WE DECLINED TO SELL WAS OFFERED AT ₹9.20 CRORE IN YEAR 3 ALONE** — eleven approaches, logged and published — which is roughly twice the entire year's profit. That is the honest measure of what this commitment costs, and stating it is the only way to make the commitment mean anything: a company that says it would never sell your data, without saying what it was offered, has told you nothing.

6. The Order History Is a Diagnosis

This is the finding, and it does not require any clever inference at all.

What was ordered	What it discloses	Who would pay for it
Antiretrovirals	HIV status	Insurers, employers
Antipsychotics, lithium, SSRIs	Mental illness and its severity	Insurers, lenders, employers
Oncology support medication	Cancer, and roughly which stage	Insurers, pharma marketers
Fertility and hormone therapy	Fertility treatment; pregnancy	Retailers, pharma marketers
Deaddiction medication	Substance dependence	Insurers, employers
Insulin, statins, antihypertensives	Chronic disease, and adherence to treatment	Insurers pricing risk
A gap in refills	That the person stopped taking his medicine — a fact his own doctor may not know	

Nothing in that table needs a model, a data scientist or a joined dataset — it is a list of molecules and their indications, which is public knowledge. That is what makes an e-pharmacy's order log different from a supermarket's: the supermarket must infer that you are pregnant, and gets it wrong; the pharmacy simply

reads it, and is right. The last row is the sharpest, because a gap in refills is a piece of information the patient never told anybody, including his doctor — and it is exactly the fact an insurer or a lender would most want and would never otherwise obtain. The dataset also grows more valuable the better the pharmacy serves people: high chronic retention means longer, cleaner, more complete histories, so **THE ASSET APPRECIATES AS A DIRECT FUNCTION OF DOING THE JOB WELL**, and the pressure to use it therefore rises every year rather than fading. Consent is not a defence: a checkbox accepted at eleven at night by somebody who is ill, in a flow designed by the party that benefits, is not a considered decision about the disclosure of a diagnosis.

So the asset is put permanently out of use rather than governed. NIL medicine data is sold, shared, segmented on or used to target — including internally, including in aggregate where the group is small enough to re-identify, and including for our own marketing. **NO THIRD-PARTY ANALYTICS OR ADVERTISING SDK RUNS ANYWHERE ON THE ORDER FLOW**, which costs ₹68 lakh in weaker attribution and dearer first-party tooling and is the single most inspectable commitment in this plan. **EVERY APPROACH IS LOGGED AND PUBLISHED WITH ITS VALUE** — eleven in Year 3, ₹9.20 crore, roughly twice the year's profit — because a company that says it would never sell your data without saying what it was offered has told you nothing. Deletion is completed within seven days and means deletion, not deactivation. **WHERE THE RECORD OF A PURCHASE IS ITSELF THE PRIVATE FACT, THE DATA IS NOT AN ASSET — HOLDING IT IS A LIABILITY YOU ACCEPTED ON THE CUSTOMER'S BEHALF.**

7. The Upload Nobody Checks and the Reminder That Sells

The anchor's refusal rule, transplanted to a channel where refusing is easier to avoid.

□ **THE PRESCRIPTION UPLOAD IS AN IMAGE, AND AN IMAGE IS NOT A PRESCRIPTION.** It can be reused across orders and across accounts, it can be months expired, it can be edited, and it can belong to somebody else entirely — and the platform's economics push in exactly one direction, because every refusal is a failed conversion in a funnel the whole organisation is measured on. Refusing is also easier to avoid than at a counter: nobody is standing in front of the reviewer, the customer's disappointment arrives as a support ticket rather than a face, and the decision can be deferred by simply approving. So **EVERY ORDER IS REVIEWED BY A REGISTERED PHARMACIST** — 58 of them, 14% of headcount — **29,400 ORDERS WERE REFUSED** in Year 3 at 18.1 per thousand, ₹2.68 crore forgone and published; reuse across accounts, editing and expiry are detected automatically with 14,900 flags raised; the prescriber is verified on 99% of flags; **AND A REVIEWER WHOSE PERSONAL REFUSAL RATE IS ZERO IS AUDITED RATHER THAN PRAISED**, per the anchor's rule that a gate with no rejections is not a gate. Reviewers are paid no bonus related to orders approved, cleared or turnaround time.

□ **THE REFILL REMINDER IS A SALES TRIGGER DRESSED AS CARE.** "Time for your refill" is genuinely useful — the anchor established that a chronic patient who stops collecting is a clinical event — but the same message is also the highest-converting promotional asset the business owns, and the two purposes are indistinguishable to the person receiving it. So **THE CLINICAL REMINDER IS SEPARATED FROM THE PROMOTION**: the refill message carries no offer, no cross-sell and no discount; discretionary-category messaging runs on its own channel that a customer can switch off without losing the reminder; and **NIL nudges of any kind are fired off a prescription signal**, at a cost of ₹1.16 crore.

□ **AND A COLD-CHAIN FAILURE IN LAST-MILE IS INVISIBLE ON ARRIVAL.** An insulin pen that spent four hours in a delivery bag looks exactly like one that did not, which per the commissary rule makes the finished product useless as evidence. So cold shipments are excursion-monitored end to end at 100%, and a failed or returned

cold delivery is **DESTROYED RATHER THAN RETURNED TO SALEABLE STOCK** — ₹42 lakh — because the alternative is selling a stranger a medicine whose history you cannot vouch for.

□ **AND THE CATEGORY'S REAL DISEASE IS THE ORDER THAT LOSES MONEY.** E-pharmacy has destroyed capital by growing gross orders while contribution after delivery stayed negative, so contribution per order after fulfilment and last-mile is reported as the primary operating metric — ₹47, ₹100, ₹126 — alongside CAC against chronic lifetime value, and no cohort is grown that does not clear it.

8. Operations Plan (review, dispense, deliver, forget)

Prescription review

- **Every order reviewed by a registered pharmacist** before dispensing; no auto-approval path exists.
- **Reuse, editing and expiry detected across accounts**, with the prescriber verified on flag.
- **Refusals published** at 18.1 per thousand orders, with revenue forgone stated.
- **Reviewers paid no bonus on approvals, clearance or turnaround**; a zero refusal rate is audited.

Data

- **No sale, sharing, segmentation or targeting on medicine data** — including internally and for our own marketing.
- **No third-party analytics or advertising SDK anywhere on the order flow.**
- **Every approach logged and published with its value** — eleven in Year 3, ₹9.20 crore.
- **Deletion completed within seven days** and meaning deletion, not deactivation.

Fulfilment and cold chain

- **Licensed dispensing site per fulfilment centre**, with the H1 register maintained per site.
- **Cold shipments excursion-monitored end to end** by logger, not by insulated bag alone.
- **Failed or returned cold deliveries destroyed**, never returned to saleable stock.
- **Distributors de-listed on a spurious or substandard batch** — 7 in Year 3 — not merely quarantined.

Customer and commercial

- **Clinical refill reminder carries no offer, cross-sell or discount.**
- **No discretionary-category nudge fired off a prescription signal, ever.**
- **Contribution per order after delivery** reported as the primary operating metric.
- **Category contribution never blended alone**; trade schemes disclosed separately.

The operational hinge arrives as a term sheet rather than a temptation: a health insurer offers a nine-figure multi-year arrangement for de-identified adherence data — refill gaps by pincode and age band, no names — and the proposal is presented by people who genuinely believe it improves population health, which it might. It is lawful with consent, it is what the category does, it is aggregate rather than individual, and it would roughly triple this company's profit at zero marginal cost. So the **DATA GOVERNANCE FUNCTION REPORTS TO THE BOARD AND HOLDS A VETO**, the answer is **NO WITHOUT A CASE-BY-CASE EVALUATION** — because a de-identification standard is a technical claim that erodes as datasets are combined, and because the aggregate offer is always how the individual one begins — the approach is **LOGGED AND PUBLISHED WITH ITS VALUE**, and no employee's compensation is affected by declining it. The system refuses rather than warns: there is no export path from the order database to any external destination, which is an engineering fact rather than a

9. Licensing, Data & Operating Compliance (India)

- **Drugs and Cosmetics Act 1940 and Rules 1945** — a retail drug licence for **each fulfilment premises** from which dispensing occurs.
- **Pharmacy Act 1948** — dispensing by or under the personal supervision of a registered pharmacist, a requirement that does not soften because the patient is at the other end of an app.
- **Schedules H, H1 and X** — H1 register maintained per dispensing site; Schedule X handled under NDPS conditions.
- **Digital Personal Data Protection Act 2023** — health data is sensitive personal data: purpose limitation, informed consent, breach notification and honoured erasure; and **NOTHING IN IT OBLIGES A PLATFORM TO DISCLOSE WHAT IT DOES WITH THE INFERENCE THAT A CUSTOMER TAKES INSULIN**, which is why the commitments above go beyond it.
- **IT Act and CERT-In directions** — security controls, logging and incident reporting.
- **NPPA and DPCO** ceiling prices; cold-chain storage and transport conditions; FSSAI for nutraceuticals.
- **Consumer protection and e-commerce rules** — dark patterns, pre-ticked consents and misleading health claims.
- **The unsettled channel** — online pharmacy regulation has been contested and repeatedly revisited, so a responsible operator runs to the **STRICTER** reading of an unsettled position rather than the more convenient one.

10. Organisation & Manpower Plan

Function	Yr 1	Yr 3	Notes
Promoter / managing director	1	1	Owens the no-monetisation rule
Registered pharmacists — prescription review	14	58	14% of headcount; no bonus on approvals
Fulfilment, packing & cold chain	42	168	Licensed dispensing site per centre
Last-mile & logistics coordination	12	44	Excursion monitoring end to end
Technology, security & data governance	18	52	Board veto; no export path from the order database
Customer care & chronic follow-up	16	62	Clinical reminder, separated from promotion
Finance, legal, compliance & admin	8	24	Publishes the approach log
Total	111	409	Pharmacists and data governance at 20%

Fifty-eight registered pharmacists reviewing 1.62 million orders is roughly one review team member per 28,000 orders a year, and it is the cost of the position that an upload is not a prescription. The important design choice is what they are NOT paid on: no bonus attaches to orders approved, orders cleared or review turnaround, because any one of those would convert a clinical judgement into a throughput target within a quarter. The data governance function sits in technology but reports to the board with a veto, and no employee's compensation is affected by declining a data proposal — which matters, because the person asked to evaluate a ₹9.20 crore offer should not be someone whose bonus improves if it is accepted.

11. Implementation Timeline & Milestones

Phase	Window	Milestones
Formation & first fulfilment centre	Month 0-7	Incorporation, drug licence, pharmacist team, platform build
No-export architecture & SDK-free order flow	Month 2-9	Engineering fact, not policy; first-party analytics only
Pharmacist review & refusal publication	Month 5-12	Reuse detection across accounts; refusal rate published
Chronic subscription programme	Month 9-20	Clinical reminder separated from promotion; retention measured
Cities two to four	Month 14-28	Licensed sites, cold-chain logging, contribution-positive cohorts
Scale & publication	Month 26-36	1.62m orders; approach log published with values; 78% retention

Training and competence

- **Prescription review judgement** — reuse, editing, expiry and prescriber verification.
- **Refusing at a distance** — how to decline an order well when there is no face and no counter.
- **Data handling** — why aggregate is not anonymous, and why internal use counts as use.
- **Cold-chain discipline** in last-mile, including why a returned cold pack cannot be restocked.

12. Financial Plan (Illustrative)

All figures are illustrative model assumptions, not forecasts or guarantees. They exist to show the drivers of an e-pharmacy P&L and how the data, review and reminder disciplines move them. Every input is editable. **The defining economics are a 23.9% blended gross margin against heavy fulfilment, delivery and acquisition cost, producing a 3.4% net margin — THINNER THAN THE PHYSICAL RETAIL PHARMACY IN THE ANCHOR PLAN, NOT FATTER, which is the fact the category's valuations have persistently ignored.**

12.1 Project cost & funding

Item	₹ lakh	Notes
Fulfilment centres, racking & cold rooms (4 cities)	486	Licensed dispensing site at each
Technology platform, security & first-party analytics	412	No third-party SDK on the order flow; no export path
Opening inventory across fulfilment centres	368	Long SKU tail across four cities
Working capital	286	Stock cycle and payment settlement
Licences, deposits & pre-operative	128	A drug licence per dispensing site
Cold-chain & last-mile equipment	84	Loggers, not insulated bags alone
Launch marketing	36	Deliberately small; CAC is the category's grave

Total project cost	1,800	₹820L investor + ₹540L term loan + ₹260L promoter + ₹180L WC
--------------------	-------	--

12.2 Operating metrics

Metric	Yr 1	Yr 2	Yr 3
MEDICINE DATA sold, shared, segmented on or used to target — including internally / third-party analytics or advertising SDK on the order flow / approaches LOGGED AND PUBLISHED with value (₹cr) / deletion completed within 7 days	NIL / NIL / 4 · 1.8 / 100%	NIL / NIL / 7 · 4.6 / 100%	NIL / NIL / 11 · 9.2 / 100%
Orders REVIEWED BY A REGISTERED PHARMACIST / orders REFUSED / per 1,000 orders / revenue forgone (₹L) / a reviewer with a ZERO refusal rate audited	100% / 3,900 / 14.0 / 34 / 100%	100% / 12,600 / 16.3 / 112 / 100%	100% / 29,400 / 18.1 / 268 / 100%
Reuse, editing and expiry detected across accounts / flags raised / prescriber verified on flag / reviewer bonus linked to approvals, clearance or turnaround	100% / 2,140 / 96% / NIL	100% / 6,800 / 98% / NIL	100% / 14,900 / 99% / NIL
Clinical refill reminder SEPARATED from promotion (no offer, cross-sell or discount) / discretionary-category nudges fired off a PRESCRIPTION SIGNAL / algorithmic supplement recommendation alongside a prescription	100% / NIL / NIL	100% / NIL / NIL	100% / NIL / NIL
Cold shipments excursion-monitored end to end / failed or returned cold deliveries DESTROYED rather than returned to saleable stock / distributors DE-LISTED on a spurious batch	100% / 100% / 2	100% / 100% / 4	100% / 100% / 7
Contribution per order AFTER fulfilment and delivery / CAC / chronic lifetime value / chronic subscriber retention / orders	₹47 / ₹410 / ₹2,180 / 58% / 279k	₹100 / ₹340 / ₹3,240 / 69% / 773k	₹126 / ₹286 / ₹4,120 / 78% / 1,622k

Row one carries the number that makes the commitment mean something: ₹9.20 crore of data approaches declined in Year 3, roughly twice the ₹4.96 crore profit, with the count and value published rather than the intention asserted. The NIL for internal use is deliberate and is the part competitors would find hardest — most platforms that would never sell health data segment on it constantly for their own marketing, which is the same disclosure with a shorter journey. Row two applies the anchor's refusal rule to a channel where refusing is easier to avoid, and the rate RISES from 14.0 to 18.1 per thousand because a rising rate means the gate is being enforced harder. Row six is the row the category has historically refused to look at: contribution per order AFTER fulfilment and delivery, ₹47 to ₹126, which is the difference between a business and a subsidised delivery habit — and CAC of ₹286 against chronic lifetime value of ₹4,120 is why chronic subscribers, not app installs, define the market this plan is addressing.

12.3 Revenue build

Stream	Yr 1 (₹L)	Yr 2 (₹L)	Yr 3 (₹L)	Gross margin
Chronic-care subscription refills	960	2,720	5,840	18.0%
Acute prescription orders	600	1,700	3,650	20.0%
OTC medicines	288	816	1,752	30.0%
Nutraceuticals, supplements & wellness	216	612	1,314	46.0%
Surgicals, devices & home diagnostics	192	544	1,168	32.0%

Fulfilment & last-mile for partner pharmacies	144	408	876	24.0%
Total revenue	2,400	6,800	14,600	23.9% blended

12.4 P&L summary

Line	Yr 1 (₹L)	Yr 2 (₹L)	Yr 3 (₹L)
Revenue	2,400	6,800	14,600
Cost of goods — incl. destroyed cold-chain returns and expiry	(1,920)	(5,270)	(11,105)
Gross profit	480	1,530	3,495
Last-mile delivery	(186)	(416)	(803)
Fulfilment centres, packing & cold chain	(164)	(342)	(657)
Customer acquisition & marketing	(248)	(386)	(438)
Technology, security & data governance	(164)	(248)	(365)
Registered pharmacist prescription review	(96)	(168)	(292)
Admin, legal, compliance & other	(94)	(164)	(263)
EBITDA	(472)	(194)	677
Depreciation & amortisation	(112)	(186)	(263)
Finance cost	(64)	(108)	(146)
Other income — supplier trade schemes and partner platform fees (<i>disclosed</i>)	118	268	394
PBT	(530)	(220)	662
Tax	133	55	(166)
PAT	(397)	(165)	496
Net margin	(16.5%)	(2.4%)	3.4%
ROCE	(32.4%)	(21.1%)	23.0%

Marketing at ₹4.38 crore is 3.0% of revenue and rises far more slowly than revenue does — ₹2.48 crore on ₹24 crore of sales in Year 1 against ₹4.38 crore on ₹146 crore in Year 3 — which is deliberate, because the category's characteristic failure is buying orders that never clear contribution after delivery. Growth here comes from chronic retention rising 58% to 78% rather than from acquisition, which is also why CAC falls while lifetime value more than doubles. Other income of ₹3.94 crore is supplier trade schemes and partner platform fees, labelled rather than buried, and it is never conditional on the volume of a specific brand. The 3.4% net margin is thinner than the physical retail pharmacy in the anchor plan, which is the fact worth sitting with: adding delivery, technology and acquisition cost to a 24% gross margin does not produce a better business than a shop, it produces a more scalable one — and ₹4.94 crore of operating commitments against ₹4.96 crore of profit means a trade-standard operator would earn ₹9.90 crore before touching the data at all.

12.5 Break-even & sensitivity

Scenario	Yr 3 revenue	Yr 3 PAT	Comment
----------	--------------	----------	---------

Base	₹146.0cr	₹4.96cr	As modelled, 3.4% net
Trade-standard operating practice	₹148.7cr	₹9.90cr	No refusals, nominal review, nudges on
Data monetised as offered	₹157.9cr	₹16.80cr	The ₹9.20cr asset this plan will not use
Discount depth +2 points to defend share	₹146.0cr	₹2.77cr	Why the category loses money
Chronic retention falls to 68%	₹134.3cr	₹3.38cr	Retention, not installs, is the business
Last-mile cost +25%	₹146.0cr	₹3.46cr	Contribution after delivery is the metric

13. Funding Requirement & Bankability

Source	₹ lakh	Terms (indicative)
Investor equity	820	Growth capital; data-use and refusal covenants
Term loan	540	Fulfilment centres, cold chain and platform; 5-6 years
Promoter contribution	260	Cash and category experience
Working capital facility	180	Stock cycle and settlement
Total	1,800	Illustrative structure

A lender or investor should read contribution per order after delivery and chronic retention, and should treat the data restriction as a covenant rather than a description — because an incoming investor will, at some point, be shown a model in which it is relaxed. Contribution per order rising ₹47 to ₹126 is the only evidence that this is a business rather than a subsidised delivery habit, and the discount sensitivity shows how quickly two points of price gives back more than half the profit. Chronic retention at 78% is the asset: it drives CAC down, lifetime value up, and it is what a competitor's discount is actually attacking. The data covenant matters most at exit, when the acquirer's valuation may rest substantially on a use of the dataset this company has promised never to make — which is a conversation worth having in the shareholders' agreement rather than in a data room.

- **Use of funds** — 27% fulfilment centres, 23% platform and security, 20% opening inventory, 16% working capital, 7% licences and deposits, 5% cold-chain equipment, 2% launch marketing.
- **Repayment** — term loan from Year 3 cash flow; working capital revolving against the stock and settlement cycle.
- **Investor exit** — sale to a healthcare group, a retail pharmacy chain seeking digital reach, or a strategic acquirer; or promoter buyback. **Data restrictions survive change of control.**

14. Risk Analysis & Mitigation

Risk	Impact	Mitigation
------	--------	------------

The order history is a diagnosis	What somebody buys from a pharmacy discloses HIV status, pregnancy and its termination, mental illness, cancer, fertility treatment and addiction — WITH NO CLINICAL RECORD, NO DOCTOR AND NO INFERENCE MORE COMPLICATED THAN READING THE MOLECULE NAME. A supermarket must INFER that you are pregnant and gets it wrong; THE PHARMACY SIMPLY READS IT AND IS RIGHT. A refill gap discloses that somebody STOPPED TAKING HIS MEDICINE — a fact HIS OWN DOCTOR MAY NOT KNOW and exactly what an insurer or lender would most want. The dataset is the most valuable asset the business owns, IT IS BUYABLE, and AS CHRONIC RETENTION IMPROVES THE ASSET APPRECIATES AS A DIRECT FUNCTION OF DOING THE JOB WELL — so the pressure to use it RISES EVERY YEAR RATHER THAN FADING. Consent is not a defence: a checkbox accepted at eleven at night by somebody who is ill, in a flow designed by the party that benefits, is NOT A CONSIDERED DECISION ABOUT THE DISCLOSURE OF A DIAGNOSIS	THE ASSET IS PUT PERMANENTLY OUT OF USE RATHER THAN GOVERNED: NIL medicine data sold, shared, segmented on or used to target — INCLUDING INTERNALLY, including in aggregate where the group is small enough to re-identify, AND INCLUDING FOR OUR OWN MARKETING (most platforms that would never SELL health data segment on it constantly for themselves, which is the same disclosure with a shorter journey). NO THIRD-PARTY ANALYTICS OR ADVERTISING SDK ANYWHERE ON THE ORDER FLOW (₹68L) — the single most INSPECTABLE commitment here, since anyone can examine the traffic. EVERY APPROACH LOGGED AND PUBLISHED WITH ITS VALUE — 11 in Yr3, ₹9.20cr, ROUGHLY TWICE THE YEAR'S PROFIT — BECAUSE A COMPANY THAT SAYS IT WOULD NEVER SELL YOUR DATA WITHOUT SAYING WHAT IT WAS OFFERED HAS TOLD YOU NOTHING. Deletion within 7 days, meaning deletion not deactivation. WHERE THE RECORD OF A PURCHASE IS ITSELF THE PRIVATE FACT, THE DATA IS NOT AN ASSET — HOLDING IT IS A LIABILITY YOU ACCEPTED ON THE CUSTOMER'S BEHALF
The insurer's term sheet	A health insurer offers a nine-figure multi-year arrangement for DE-IDENTIFIED adherence data — refill gaps by pincode and age band, no names — presented by people who GENUINELY BELIEVE IT IMPROVES POPULATION HEALTH, WHICH IT MIGHT. It is lawful with consent, it is what the category does, it is aggregate rather than individual, and it would ROUGHLY TRIPLE THIS COMPANY'S PROFIT AT ZERO MARGINAL COST	DATA GOVERNANCE REPORTS TO THE BOARD WITH A VETO; the answer is NO WITHOUT A CASE-BY-CASE EVALUATION, because A DE-IDENTIFICATION STANDARD IS A TECHNICAL CLAIM THAT ERODES AS DATASETS ARE COMBINED and because THE AGGREGATE OFFER IS ALWAYS HOW THE INDIVIDUAL ONE BEGINS; the approach is LOGGED AND PUBLISHED WITH ITS VALUE; and NO EMPLOYEE'S COMPENSATION IS AFFECTED BY DECLINING IT — the person evaluating a ₹9.20cr offer must not be someone whose bonus improves if it is accepted. THE SYSTEM REFUSES RATHER THAN WARNS: THERE IS NO EXPORT PATH FROM THE ORDER DATABASE TO ANY EXTERNAL DESTINATION, WHICH IS AN ENGINEERING FACT RATHER THAN A POLICY. Data restrictions SURVIVE CHANGE OF CONTROL, because an acquirer's valuation may rest on exactly the use we promised never to make

An upload is not a prescription	The image can be REUSED ACROSS ORDERS AND ACCOUNTS, months EXPIRED, EDITED, or belong to SOMEBODY ELSE ENTIRELY — and every refusal is a FAILED CONVERSION in the funnel the whole organisation is measured on. Refusing is EASIER TO AVOID THAN AT A COUNTER: nobody is standing in front of the reviewer, the disappointment arrives as a support ticket rather than a face, and THE DECISION CAN BE DEFERRED BY SIMPLY APPROVING	EVERY ORDER REVIEWED BY A REGISTERED PHARMACIST — 58 of them, 14% of headcount, NO AUTO-APPROVAL PATH EXISTS; 29,400 ORDERS REFUSED in Yr3 at 18.1 per 1,000, RISING from 14.0 because a rising rate means harder enforcement, ₹2.68cr forgone AND PUBLISHED; reuse, editing and expiry detected ACROSS ACCOUNTS with 14,900 flags and the prescriber verified on 99%; A REVIEWER WITH A ZERO PERSONAL REFUSAL RATE IS AUDITED RATHER THAN PRAISED (anchor rule: a gate with no rejections is not a gate); and NO REVIEWER BONUS attaches to orders approved, cleared or turnaround time, because any one of those converts a clinical judgement into a throughput target within a quarter
The reminder that sells	"Time for your refill" is GENUINELY USEFUL — the anchor established a chronic patient who stops collecting is a clinical event — but it is ALSO THE HIGHEST-CONVERTING PROMOTIONAL ASSET THE BUSINESS OWNS, and THE TWO PURPOSES ARE INDISTINGUISHABLE TO THE PERSON RECEIVING IT	THE CLINICAL REMINDER IS SEPARATED FROM THE PROMOTION: the refill message carries NO offer, cross-sell or discount; discretionary-category messaging runs on ITS OWN CHANNEL THAT A CUSTOMER CAN SWITCH OFF WITHOUT LOSING THE REMINDER; and NIL nudges of any kind fire off a PRESCRIPTION SIGNAL (₹1.16cr). A customer buying metformin is NEVER shown a diabetes supplement, because the recommendation would be built on A DIAGNOSIS HE DISCLOSED IN ORDER TO BE DISPENSED, NOT IN ORDER TO BE MARKETING TO
The margin ladder, automated	The anchor's ladder reappears in worse form: at a counter the supplement is suggested by a person who can see the patient and MIGHT NOT BOTHER; online it is A RULE THAT FIRES ON EVERY QUALIFYING ORDER, AT SCALE, AT NO MARGINAL COST, FOREVER — and IT NEVER HAS A BAD DAY OR AN ATTACK OF CONSCIENCE. Nutraceuticals at 46% gross against chronic refills at 18%	STRICTER THAN THE ANCHOR'S DISCLOSURE RULE: NO ALGORITHMIC RECOMMENDATION OF A DISCRETIONARY CATEGORY FIRES OFF A PRESCRIPTION SIGNAL AT ALL — NOT DISCLOSED, NOT DONE. Category contribution reported separately and never blended alone; supplier trade schemes and partner platform fees (₹3.94cr) disclosed as a line and NEVER conditional on the volume of a specific brand
Cold-chain failure in last-mile	An insulin pen that spent four hours in a delivery bag LOOKS EXACTLY LIKE ONE THAT DID NOT — per the commissary rule, the finished product is useless as evidence — and a returned cold delivery has a history nobody can vouch for	Cold shipments EXCURSION-MONITORED END TO END by logger at 100%, not by insulated bag alone; failed or returned cold deliveries DESTROYED rather than returned to saleable stock (₹42L); distributors DE-LISTED on a spurious or substandard batch — 7 in Yr3 — rather than the batch merely quarantined, per the anchor and the spice-brand rule that a returned batch is simply sold to somebody else

The order that loses money	E-pharmacy has destroyed more capital than almost any Indian consumer category by GROWING GROSS ORDERS WHILE CONTRIBUTION AFTER DELIVERY STAYED NEGATIVE; two points of discount depth takes profit to ₹2.77cr and a 25% last-mile cost rise to ₹3.46cr	CONTRIBUTION PER ORDER AFTER FULFILMENT AND DELIVERY reported as the PRIMARY operating metric — ₹47 → ₹100 → ₹126 — with no cohort grown that does not clear it; marketing held at 3.0% of revenue and falling as a share; growth taken from CHRONIC RETENTION 58%→78% rather than acquisition, which is why CAC falls to ₹286 while lifetime value reaches ₹4,120; and route density built city by city rather than nationally
Regulatory unsettledness in the online channel	Online pharmacy regulation has been CONTESTED AND REPEATEDLY REVISITED, so a convenient reading today can become a licence problem tomorrow across four cities at once	Run to the STRICTER reading of an unsettled position rather than the more convenient one: a licensed dispensing site with its own drug licence and H1 register at every fulfilment centre; registered-pharmacist supervision treated as mandatory regardless of channel; Schedule X handled under NDPS conditions; DPDP Act treated as a floor rather than a ceiling; CERT-In logging and breach procedures live; and no marketing claim made about medicines that could not be made across a counter

15. SWOT Analysis

Strengths • Nil medicine data sold, shared or segmented — including internally • No third-party analytics or ad SDK on the order flow • ₹9.20cr of data approaches logged, published and declined • Every order reviewed by a pharmacist; 18.1 refusals per 1,000 • Contribution per order after delivery ₹126; retention 78%	Weaknesses • ₹4.94cr of commitments against ₹4.96cr of profit • 3.4% net — thinner than a physical pharmacy, not fatter • Weaker attribution and dearer first-party tooling • Declines the most valuable asset the business owns
Opportunities • Chronic subscribers as a retention-led, low-CAC business • Privacy as an inspectable rather than asserted claim • Fulfilment capacity sold to partner pharmacies • Home diagnostics adjacency at the same delivery cost • DPDP enforcement raising the floor for everybody	Threats • Discount-led competition from funded rivals • Quick-commerce speed targets incompatible with review • Regulatory reversal in the online channel • An acquirer valuing the dataset we will not use

16. Recommended AiSevak Tools for This Business

- **No-export order database** — architecturally incapable of sending order data to any external destination.
- **Data approach register** — every offer logged with its value, published, with board veto attached.
- **Pharmacist review queue** — no auto-approval path; refusals logged; zero-rate reviewers auto-audited.
- **Prescription reuse detector** — same image across orders and accounts, expiry, edit detection.
- **Reminder separation engine** — clinical refill messages structurally incapable of carrying an offer.
- **Cold-chain logger integration** — end-to-end excursion capture with automatic destruction routing.

- **Contribution-per-order dashboard** — after fulfilment and delivery, by cohort and city.

17. Key Assumptions & Notes

- **All financials are illustrative model assumptions, not forecasts, projections or guarantees.** Revenue, order volumes, category margins, refusal counts, retention and CAC are editable inputs; actual outcomes depend on city density, discounting, regulation and delivery cost. Figures are in Indian rupees. **This plan inherits the pharmacy vertical anchor's ten rules from `retail-pharmacy` and extends them to a channel with no counter.**
- **The central integrity finding is that a medicine order history is a diagnosis.** What somebody buys from a pharmacy discloses HIV status, pregnancy and its termination, mental illness, cancer, fertility treatment and addiction — with no clinical record required, no doctor involved and no inference more complicated than reading the molecule name. **A supermarket must infer that you are pregnant and gets it wrong; the pharmacy simply reads it and is right. A gap in refills discloses that somebody stopped taking his medicine, a fact his own doctor may not know and precisely what an insurer or a lender would most want and could never otherwise obtain. The dataset is the most valuable asset the business owns, it is buyable, and because it appreciates as chronic retention improves, THE ASSET GROWS MORE VALUABLE AS A DIRECT FUNCTION OF DOING THE JOB WELL — so the pressure to use it rises every year rather than fading. Consent is not a defence: a checkbox accepted at eleven at night by somebody who is ill, in a flow designed by the party that benefits, is not a considered decision about the disclosure of a diagnosis.**
- **So the asset is put permanently out of use rather than governed.** Nil medicine data is sold, shared, segmented on or used to target — including internally, including in aggregate where the group is small enough to re-identify, and including for our own marketing, which is the part competitors would find hardest, since most platforms that would never sell health data segment on it constantly for themselves. No third-party analytics or advertising SDK runs anywhere on the order flow, at ₹68 lakh and as the single most inspectable commitment in the plan. **Every approach is logged and published with its value — eleven in Year 3 at ₹9.20 crore, roughly twice the year's profit — because a company that says it would never sell your data without saying what it was offered has told you nothing. WHERE THE RECORD OF A PURCHASE IS ITSELF THE PRIVATE FACT, THE DATA IS NOT AN ASSET — HOLDING IT IS A LIABILITY YOU ACCEPTED ON THE CUSTOMER'S BEHALF.**
- **The hardest version of the test is not a data broker but a health insurer with a good argument.** A nine-figure offer for de-identified adherence data — refill gaps by pincode and age band, no names — lawful with consent, aggregate rather than individual, presented by people who genuinely believe it improves population health, and worth roughly three times this company's profit at zero marginal cost. **The answer is no without a case-by-case evaluation, because a de-identification standard is a technical claim that erodes as datasets are combined, and because the aggregate offer is always how the individual one begins. Data governance reports to the board with a veto, no employee's compensation is affected by declining, and there is no export path from the order database to any external destination — an engineering fact rather than a policy. The restrictions survive change of control, because an acquirer's valuation may rest on exactly the use we promised never to make.**
- **The anchor's refusal rule transplants to a channel where refusing is easier to avoid.** An upload is an image, not a prescription: reusable across orders and accounts, expirable, editable, often somebody else's — and every refusal is a failed conversion in a funnel the whole organisation is measured on, with the customer's disappointment arriving as a support ticket rather than a face. **Every order is reviewed by a registered pharmacist with no auto-approval path; 29,400 orders were refused in Year 3 at 18.1 per thousand, rising from 14.0 because a rising rate means harder enforcement, with ₹2.68 crore forgone and published; a reviewer whose personal refusal rate is zero is audited rather than praised; and no reviewer bonus attaches to approvals, clearance or turnaround, because any one of those converts a clinical judgement into a throughput target within a**

quarter.

- **The refill reminder is a sales trigger dressed as care, and the margin ladder is worse online than at a counter.** The clinical reminder carries no offer, cross-sell or discount; discretionary messaging runs on a channel a customer can switch off without losing the reminder; and nil nudges fire off a prescription signal, at ₹1.16 crore. **At a counter a supplement is suggested by a person who can see the patient and might not bother; online it is a rule that fires on every qualifying order, at scale, at no marginal cost, and it never has a bad day or an attack of conscience — so the rule here is stricter than the anchor's: no algorithmic recommendation of a discretionary category fires off a prescription signal at all. Not disclosed — not done.** A customer buying metformin is never shown a diabetes supplement, because that recommendation would be built on a diagnosis he disclosed in order to be dispensed, not in order to be marketed to.
- **The economics are thinner than the shop, not fatter, and the plan says so.** A 23.9% blended gross margin against fulfilment, last-mile, technology and acquisition cost produces 3.4% net — below the physical retail pharmacy in the anchor plan — which is the fact the category's valuations have persistently ignored. **Contribution per order after fulfilment and delivery, ₹47 to ₹126, is reported as the primary operating metric, because e-pharmacy has destroyed capital by growing gross orders while that number stayed negative; growth comes from chronic retention rising 58% to 78% rather than from acquisition, which is why CAC falls to ₹286 while lifetime value reaches ₹4,120.** Operating commitments of ₹4.94 crore against ₹4.96 crore of profit mean a trade-standard operator would earn ₹9.90 crore before touching the data at all, and ₹16.80 crore after.
- **Compliance and professional advice.** The Drugs and Cosmetics Act 1940 and Rules 1945 with a retail drug licence for each fulfilment premises; the Pharmacy Act 1948, under which registered-pharmacist supervision does not soften because the patient is at the other end of an application; Schedules H, H1 and X with the register maintained per dispensing site and Schedule X under NDPS conditions; the Digital Personal Data Protection Act 2023, under which health data is sensitive personal data requiring purpose limitation, consent, breach notification and honoured erasure — treated here as a floor rather than a ceiling; the IT Act and CERT-In directions; NPPA and DPCO ceiling prices; cold-chain storage and transport conditions; FSSAI for nutraceuticals; consumer protection and e-commerce rules on dark patterns and pre-ticked consents; GST, EPF/ESI and POSH. **Because the online channel's framework has been contested and repeatedly revisited, professional advice should be taken on the current position in each state, and the stricter reading adopted where it is unsettled.**

► **Use these tools now — free on AiSevak**

Every tool referenced in this plan is available on aisevak.in. Open the [Pharmacy Retail & Distribution toolkit](#) to browse and use them all at <https://aisevak.in/verticals/pharmacy> — or go straight to any specific tool at <https://aisevak.in/service/<tool-name>>. No signup needed to explore; each tool guides you step by step.

Prepared by AiSevak.in — a product of ABL Digital Technologies. AI-powered business services for India. This is AI-assisted guidance; figures are illustrative and not a guarantee of results. Verify all numbers, licences and regulatory requirements with a qualified professional before relying on this plan for binding decisions. © 2026 ABL Digital Technologies Private Limited.